1. Suppl. Fig. 2 A B Evaluation of FasL-induced apoptosis in BM-MSCs.
Cntrl
FasL
25ng/ml A
Pro-caspase 3
Actin B
zVAD
0.5 FasL
25 FasL
HuT78
0.5 FasL +zVAD
25 FasL +zVAD
5 FasL
α-Fas
25 FasL +α-Fas
25 FasL+ zVAD
day 1
day 2
day 4
day 6
35 KDa
43 KDa
Evaluation of FasL-induced apoptosis in BM-MSCs.
A) BM-MSCs were plated on chamber slides at a density of 5×103 cells/cm2 and treated with 25 ng/ml FasL for 1, 2, 4, or 6 days. After fixation they were stained with Hoechst to show nuclei (arrows, pycnotic nuclei). B) Original caspase 3 western blots from batch # 1 BM-MSCs treated with 0.5 ng/ml FasL (0.5 FasL), 25 ng/ml FasL (25 FasL), or pretreated with the caspase inhibitor zVAD before FasL treatment (0.5 FasL zVAD, 25 FasL zVAD). Untreated cells (cntrl) and zVAD-supplemented cells (zVAD) were used as controls. HuT78 cell line treated with 25ng/ml FasL for 5 hours were used as caspase-3 activation positive control.
19/17 KDa
active fragments